Apatinib Prompts Responses in Patients With Recurrent Melanoma

Source: AJMC, May 2022

The drug yielded partial responses in 2 of 15 patients in this single-arm, phase 2 study.

Apatinib (Rivoceranib) may be a suitable second-line treatment option for a subset of patients with recurrent or refractory melanoma, according to a new report.

Molecular-targeted therapy and immunotherapy have dramatically changed the treatment of patients with advanced melanoma in recent years, noted corresponding author Quanli Gao, MD, PhD, of the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, in China. BRAF and MEK inhibitors, as well as immune checkpoint inhibitors, have led to promising results and extended progression-free survival (PFS), Gao and colleagues said. Yet, not all patients respond to these therapies, and in such cases, there is no recommended treatment option.